Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 127, Issue 8, Pages 2998-3012Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI92026
Keywords
-
Categories
Funding
- Cancer Prevention and Research Institute of Texas [RR140053]
- Innovation Award from American Heart Association [16IRG27250155]
- John S. Dunn Foundation Collaborative Research Award
- Translational Research Program (TRP) of the Leukemia and Lymphoma Society [6464-15]
- NIH [R01GM112003]
- Welch Foundation [BE-1913]
- American Cancer Society [RSG-16-215-01-TBE]
- Texas AM University
- National Cancer Institute, NIH [R01 CA164346, R01 CA200703]
- Developmental Research Award in Leukemia [SPORE CA100632]
- Developmental Research Award in CPRIT [RP140402]
Ask authors/readers for more resources
Angioimmunoblastic T cell lymphoma (AITL) represents a distinct, aggressive form of peripheral T cell lymphoma with a dismal prognosis. Recent exome sequencing in patients with AITL has revealed the frequent coexistence of somatic mutations in the Rho GTPase RhoA (RhoA(G17V)) and loss-of-function mutations in the 5-methylcytosine oxidase TET2. Here, we have demonstrated that TET2 loss and RhoA(G17V) expression in mature murine T cells cooperatively cause abnormal CD4(+) T cell proliferation and differentiation by perturbing FoxO1 gene expression, phosphorylation, and subcellular localization, an abnormality that is also detected in human primary AITL tumor samples. Reexpression of FoxO1 attenuated aberrant immune responses induced in mouse models adoptively transferred with T cells and bearing genetic lesions in both TET2 and RhoA. Our findings suggest a mutational cooperativity between epigenetic factors and GTPases in adult CD4(+) T cells that may account for immunoinflammatory responses associated with AITL patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available